Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817866 · ClinicalTrials.gov registry record
Chromogranin A as Blood Marker in Cancer Patients
A clinical trial of Colorectal Neoplasms and Pancreatic Neoplasms, sponsored by Brahms.
- Completed
- Registry status
- 175
- Enrollment target
- 4
- Study locations
NCT03817866: Completed study of Colorectal Neoplasms and Pancreatic Neoplasms, sponsored by Brahms.
NCT03817866 is a study of Colorectal Neoplasms and Pancreatic Neoplasms that has completed, run by Brahms. The registered enrollment target is 175 participants, below the 573-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (69% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03817866, a study of Colorectal Neoplasms and Pancreatic Neoplasms, has completed, sponsored by Brahms.
- COMPLETED
- Registry status
- 175 participants
- Enrollment target
- 4
- Study locations
Study Summary
Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs. Due to the lack of symptoms in the early stage of disease and the frequency of nonspecific GI symptoms, GEP-NETs are difficult to diagnose. Identification of effective biomarkers (such as Chromogranin A) to improve GEP-NET diagnosis, as well as to assess treatment efficacy, relapse and prognosis, is important for improving outcomes for patients with GEP-NETs. The purpose of this study is to validate the performance of Brahms (BRAHMS) Chromogranin A II Kryptor (KRYPTOR) assay to monitor the course of disease in patients with well-defined GEP-NETs.
Primary Outcome
Progression vs. non-progression in patients with well-defined GEP-NETs assessed by RECIST 1.1 criteria
Conditions Studied
Interventions
- DIAGNOSTIC_TEST BRAHMS CgA II KRYPTOR
Study Locations (4)
California
- Stanford University Medical Center - Palo Alto
Minnesota
- Mayo Clinic - Rochester
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Other
- Charité - Universitätsmedizin Berlin - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2019-01-29 |
| Est. Completion | 2021-12-14 |
What the finished NCT03817866 record still lists
NCT03817866 is an observational study that tracks outcomes without assigning an intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 573-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (69% lower).
The record links to 4 conditions, with Colorectal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which BRAHMS CgA II KRYPTOR is the first listed.
NCT03817866 reports a single indexed study location in California, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT03817866 about?
NCT03817866 is a clinical study titled "Chromogranin A as Blood Marker in Cancer Patients". Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs. Due to the lack of symptoms in the early stage of disease and the frequ...
What is the current status of trial NCT03817866?
This trial is currently completed. The enrollment target is 175 participants. The study started on 2019-01-29. Estimated completion is 2021-12-14.
What conditions does trial NCT03817866 study?
This clinical trial studies the following conditions: Colorectal Neoplasms, Pancreatic Neoplasms, Gastric Neoplasms, Small Intestinal Neoplasms.
What interventions are being tested in trial NCT03817866?
The interventions under investigation include: BRAHMS CgA II KRYPTOR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03817866?
This trial is sponsored by Brahms, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817866 being conducted?
This trial has 4 study locations across California, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03817866's enrollment target sits among peer trials
175 32nd of 54 higher than 23 of 54 other Colorectal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
RECRUITING · Phase 3
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI